Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.36 +3.8%	$1.36	$0.86 ▼ $3.36	$82.38M	0.14	327,865 shs	93,852 shs
EPIX ESSA Pharma	$0.24 +2.1%	$1.72	$0.22 ▼ $7.88	$11.35M	1.55	2.19 million shs	9.76 million shs
IMUX Immunic	$0.82 -5.7%	$0.87	$0.56 ▼ $2.11	$80.89M	1.39	1.24 million shs	1.37 million shs
NNVC NanoViricides	$1.39 -1.8%	$1.51	$0.94 ▼ $2.02	$22.34M	0.96	238,649 shs	109,378 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-5.76%	-3.68%	-5.07%	+28.43%	-52.71%
EPIX ESSA Pharma	-4.32%	-87.76%	-87.43%	-86.01%	-95.52%
IMUX Immunic	+2.35%	-7.93%	-11.16%	+32.00%	-38.30%
NNVC NanoViricides	-0.35%	+3.28%	-16.76%	-6.91%	-25.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.2142 of 5 stars	3.5	5.0	2.3	1.7	0.6
EPIX ESSA Pharma	3.1263 of 5 stars	3.0	3.0	2.5	3.3	1.3
IMUX Immunic	2.7028 of 5 stars	3.6	1.0	3.1	2.5	0.6
NNVC NanoViricides	0.4345 of 5 stars	0.0	5.0	1.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$7.00	420.45% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	716.33% Upside
IMUX Immunic	3.29	Buy	$7.50	791.80% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NNVC, IMUX, ABOS, and EPIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	ABOS Acumen Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $9.00
8/8/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.93 per share	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.30 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	$0.34 per share	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	11/11/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.56	N/A	N/A	N/A	N/A	-21.71%	-21.22%	N/A
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-461.46%	-217.16%	11/6/2025 (Estimated)
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A

Latest NNVC, IMUX, ABOS, and EPIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q3 2025	EPIX ESSA Pharma	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/7/2025	Q2 2025	IMUX Immunic	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A

Latest NNVC, IMUX, ABOS, and EPIX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/1/2100	EPIX ESSA Pharma	--	$1.69		8/25/2025	8/19/2025	8/22/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.26	5.97	5.97
EPIX ESSA Pharma	N/A	69.06	69.06
IMUX Immunic	N/A	2.19	2.19
NNVC NanoViricides	N/A	3.44	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
EPIX ESSA Pharma	75.12%
IMUX Immunic	51.82%
NNVC NanoViricides	10.30%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
EPIX ESSA Pharma	15.50%
IMUX Immunic	4.60%
NNVC NanoViricides	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
EPIX ESSA Pharma	50	47.31 million	39.98 million	Optionable
IMUX Immunic	70	98.65 million	94.11 million	Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable

NNVC, IMUX, ABOS, and EPIX Headlines

Recent News About These Companies

NanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer Resurgence

August 27 at 8:49 AM | theglobeandmail.com

NanoViricides says broad-spectrum antiviral candidate NV-387 could address current, emerging and future COVID strains

August 27 at 8:47 AM | proactiveinvestors.com

NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infections

August 18, 2025 | proactiveinvestors.com

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

August 18, 2025 | accessnewswire.comA

NanoViricides says antiviral candidate NV-387 could address global measles surge

July 30, 2025 | proactiveinvestors.com

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

July 30, 2025 | accessnewswire.comA

NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

July 23, 2025 | proactiveinvestors.com

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

July 23, 2025 | accessnewswire.comA

Measles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025 | usatoday.com

NanoViricides says lead antiviral boosted survival in measles-infected mice

July 21, 2025 | proactiveinvestors.com

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025 | accessnewswire.comA

NanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox disease

July 18, 2025 | pharmabiz.comP

WHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025 | azcentral.comA

NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency

July 16, 2025 | proactiveinvestors.com

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025 | accessnewswire.comA

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

July 15, 2025 | proactiveinvestors.com

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

July 15, 2025 | proactiveinvestors.com

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox

July 15, 2025 | finance.yahoo.com

NanoViricides nears completion of clinical trial design for MPox treatment

July 14, 2025 | proactiveinvestors.com

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

July 14, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC, IMUX, ABOS, and EPIX Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.36 +0.05 (+3.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 0.00 (0.00%)

As of 04:26 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

ESSA Pharma NASDAQ:EPIX

$0.24 +0.01 (+2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$0.24 0.00 (-1.25%)

As of 05:41 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Immunic NASDAQ:IMUX

$0.82 -0.05 (-5.75%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 +0.00 (+0.24%)

As of 05:39 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

NanoViricides NYSE:NNVC

$1.39 -0.03 (-1.77%)

Closing price 03:59 PM Eastern

Extended Trading

$1.41 +0.02 (+1.37%)

As of 05:01 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time